Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parsaclisib - Incyte Corporation

Drug Profile

Parsaclisib - Incyte Corporation

Alternative Names: IBI-376; INCB-050465; INCB-50465

Latest Information Update: 26 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Innovent Biologics
  • Class Antineoplastics; Pyrazoles; Pyrimidines; Pyrrolidines
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Autoimmune haemolytic anaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Myelofibrosis; Sjogren's syndrome
  • Phase I/II B-cell lymphoma; Haematological malignancies; Solid tumours
  • Preclinical Cancer; Systemic lupus erythematosus

Most Recent Events

  • 13 Jan 2020 MorphoSys and Incyte Corporation plan a clinical trial in B-cell malignancies (Combination therapy, Second-line therapy or greater)
  • 02 Jan 2020 Incyte Corporation completes a phase-II trial in Sjogren's syndrome in USA (PO) (NCT03627065)
  • 29 Oct 2019 UNC Lineberger Comprehensive Cancer Center and Incyte Corporation plans a phase I trial for Breast cancer (Monotherapy) (PO) (NCT04142554)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top